Electra Therapeutics closed an oversubscribed $183 million Series C to fund a global pivotal trial of ELA026, its monoclonal antibody candidate for secondary hemophagocytic lymphohistiocytosis (sHLH), and to advance follow‑on programs in oncology and immunology. The financing brings Electra’s total capital to over $300 million since inception. ELA026 targets SIRP family receptors to selectively deplete pathologic myeloid and T cell populations that drive cytokine storms; the SURPASS registrational study has dosed first patients. Electra plans to use proceeds to complete SURPASS and advance ELA822 into clinical studies. Investors included institutional life‑science funds and the round positions Electra to pursue accelerated regulatory pathways in a high‑unmet rare‑disease area. For readers: sHLH is an acute, often fatal hyperinflammatory syndrome where rapid immunomodulation and cell‑depleting biologics can be disease‑altering.